<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545231</url>
  </required_header>
  <id_info>
    <org_study_id>Pitavastatin</org_study_id>
    <nct_id>NCT02545231</nct_id>
  </id_info>
  <brief_title>Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis, Endothelial Function, Circulating microRNAs, and Cardiovascular Events in Patients With Coronary Artery Disease Requiring Stent Implantation: OCT and NIRS Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare low dose (1mg) pitavastatin and high dose (4mg) pitavastatin on neointimal
      hyperplasia and atherosclerosis progression by using optical coherence tomography (OCT) and
      near-infrared spectroscopy (NIRS) at 12 months follow-up and on clinical adverse
      cardiovascular events during 3-year follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients with non-ST elevation ACS will be randomized into pitavastatin 1mg or 4mg after
           everolimus-eluting stent implantation with OCT and NIRS study.

        -  12 months follow-up coronary angiography with OCT and NIRS will be performed to compare
           neointimal hyperplasia and atherosclerosis progression.

        -  36 months clinical follow-up for major adverse cardiovascular events (cardiac death,
           all-cause death, myocardial infarction, stroke, target lesion revascularization) will be
           compared.

        -  Safety issues such as bleeding rates, abnormal liver function will be compared
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neointimal volume with OCT (mm3 per 1mm) and lipid volume with NIRS (the maximal lipid core burden index (LCBI) in 4 mm segment during 12 months of treatment</measure>
    <time_frame>12 months for OCT and NIRS</time_frame>
    <description>OCT will measure neointimal volume in every mm interval and will be averaged by dividing the total neointimal volume with the number of the segment analyzed. LCBI is the lipid volume index which is calculated automatically by the device, and LCBI &gt; 400 is considered high lipid volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of major adverse cardiovascular events during 12 months follow-up</measure>
    <time_frame>12 months for clinical events</time_frame>
    <description>Major adverse cardiovascular events include all-cause death, cardiovascular death, myocardial infarction, stroke, target vessel revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Neointima</condition>
  <condition>Angina</condition>
  <arm_group>
    <arm_group_label>Low dose 1mg pitavastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pitavastatin 1mg which is considered low dose statin will be administered for 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose 4mg pitavastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pitavastatin 4mg which is considered high dose statin will be administered for 36 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin 1mg</intervention_name>
    <description>To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia</description>
    <arm_group_label>Low dose 1mg pitavastatin</arm_group_label>
    <other_name>Livalo 1mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin 4mg</intervention_name>
    <description>To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia</description>
    <arm_group_label>High dose 4mg pitavastatin</arm_group_label>
    <other_name>Livalo 4mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia</description>
    <arm_group_label>Low dose 1mg pitavastatin</arm_group_label>
    <arm_group_label>High dose 4mg pitavastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures

          2. Patients between the age of 30 to 79

          3. Non-ST elevation Acute coronary syndrome with successful everolimus eluting stent
             implantation (with TIMI flow grade 3 after the procedure)

        Exclusion Criteria:

          1. Hypersensitivity to pitavastatin

          2. Unable to perform OCT and NIRS

          3. Serum creatinine &gt; 2.0 mg/dL.

          4. Steroid or hormone replacement therapy

          5. Hemoglobin A1c &gt;9%

          6. Type 1 diabetes

          7. Decreased serum platelet level (&lt; 100,000/uL)

          8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin

          9. Life expectancy less than a year

         10. Renal failure requiring dialysis or anticipated need for dialysis during the course of
             the study

         11. Any condition which in the opinion of the investigator would make it unsafe or
             unsuitable for the patient to participate in this study

         12. Involvement in the planning and/or conduct of the study

         13. Left ventricular ejection fraction &lt; 40%

         14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase &gt; twice
             the upper limit)

         15. Gastrointestinal disorder such as Crohn`s disease

         16. Alcohol abuse

         17. Known pregnancy, breast-feeding, or intend to become pregnant during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Do-Sun Lim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Soon Jun Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Neointima</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

